2. Academic Validation
  3. Adoptive T-cell immunotherapy for ganciclovir-resistant CMV disease after lung transplantation

Adoptive T-cell immunotherapy for ganciclovir-resistant CMV disease after lung transplantation

  • Clin Transl Immunology. 2015 Mar 27;4(3):e35. doi: 10.1038/cti.2015.5.
Chien-Li Holmes-Liew 1,  Mark Holmes 1,  Leone Beagley 2,  Peter Hopkins 3,  Daniel Chambers 3,  Corey Smith 2,  Rajiv Khanna 2
Affiliations

Affiliations

  • 1 South Australian Lung Transplant Unit, Department of Thoracic Medicine, Royal Adelaide Hospital , Adelaide, South Australia, Australia ; Faculty of Health Sciences, School of Medicine, University of Adelaide , Adelaide, South Australia, Australia.
  • 2 QIMR Centre for Immunotherapy and Vaccine Development, QIMR Berghofer Medical Research Institute , Brisbane, Queensland, Australia.
  • 3 Queensland Lung Transplant Service, The Prince Charles Hospital , Brisbane, Queensland, Australia ; School of medicine, The University of Queensland , Brisbane, Queensland, Australia.
PMID: 25859390 DOI: 10.1038/cti.2015.5
Abstract

Infections with cytomegalovirus (CMV) can induce severe complications after solid organ transplantation (SOT). The prognosis for ganciclovir-resistant CMV Infection and disease is particularly poor. Whereas adoptive transfer of CMV-specific T cells has emerged as a powerful tool in hematopoietic stem cell transplant patients, its translation into the SOT setting remains a significant challenge as underlying immunosuppression inhibits the virus-specific T-cell response in vivo. Here, we demonstrate successful expansion and adoptive transfer of autologous CMV-specific T cells from a seronegative recipient of a seropositive lung allograft with ganciclovir-resistant CMV disease, resulting in the long-term reconstitution of protective anti-viral immunity, CMV Infection, disease-free survival and no allograft rejection.

Figures
Products